Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760035 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL26192643 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL20078294 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL862847 | 0.96 | — | — | |
| SCHEMBL19309079 | 0.91 | MEN1 (0.56) | ALDH1A1TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL5155263 | 0.91 | MEN1 (0.56) | ALDH1A1TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL12893042 | 0.89 | SMN1; SMN2 (0.41) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL14924288 | 0.89 | SMN1; SMN2 (0.41) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL13113468 | 0.89 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL5157716 | 0.89 | MAPK1 (0.55) | ALDH1A1TSHRMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086577-A1 | METHODS OF REDUCING OR PREVENTING METASTASES | FOGHORN THERAPEUTICS INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023196567-A2 | METHODS OF TREATING A SUBJECT HAVING CLINICALLY SIGNIFICANT SIGNS AND SYMPTOMS ASSOCIATED WITH BLOOD CELL DIFFERENTIATION | FOGHORN THERAPEUTICS INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230304932-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS INVOLVING ENERGY TRANSFER DYE CONJUGATES AND ANALYTES COMPRISING THE SAME | Life Technologies Corporation | 2023-09-28 | — | — | US | disclosed |
| US-20220016083-A1 | METHODS OF TREATING CANCERS | FOGHORN THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2021236080-A1 | METHODS OF TREATING CANCERS | FOGHORN THERAPEUTICS INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20210251988-A1 | METHODS OF TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-08-19 | — | — | US | disclosed |
| WO-2021108662-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | DTX PHARMA, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-8937048-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2015-01-20 | — | — | US | disclosed |
| US-8937048-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2015-01-20 | — | — | US | disclosed |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2012-12-20 | — | — | US | disclosed |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2012-12-20 | — | — | US | disclosed |
| EP-0975669-A1 | CALCITONIN RECEPTOR-BINDING PEPTIDES | Diatide, Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998049196-A1 | CALCITONIN RECEPTOR-BINDING PEPTIDES | DIATIDE, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0702570-A1 | TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION | Diatide, Inc. (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994028942-A1 | TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION | DIATECH, INC. (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251988-A1 | METHODS OF TREATING DISORDERS | POLI, TFEB, VHL | ALDH1A1 2310/4885TSHR 4750/4885THRB 4242/4885 |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | ALDH1A1 2557/4885TSHR 2871/4885THRB 3214/4885 |
| US-20220016083-A1 | METHODS OF TREATING CANCERS | VHL, HNRNPH3, SMARCC2 | ALDH1A1 1161/4885TSHR 3924/4885THRB 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.